Monitoring the Safety of Medicines Used Off-Label
Author:
- 4 April 2012
- journal article
- review article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 91 (5) , 787-795
Abstract
Off-label use of medicines is common. Because many off-label uses have not been carefully studied, it is important that postmarketing drug safety systems be able to identify, assess, and monitor adverse events that occur in the off-label setting. The full range of postmarketing surveillance and analysis tools can be utilized to study the adverse effects of medicines used off-label.Keywords
This publication has 25 references indexed in Scilit:
- Description of hypersensitivity adverse events following administration of heparin that was potentially contaminated with oversulfated chondroitin sulfate in early 2008Pharmacoepidemiology and Drug Safety, 2010
- U.S. physician knowledge of the FDA‐approved indications and evidence base for commonly prescribed drugs: results of a national surveyPharmacoepidemiology and Drug Safety, 2009
- Off-Label Prescribing to Children in the United States Outpatient SettingAcademic Pediatrics, 2009
- Frequency of ill‐founded off‐label prescribing in Dutch general practicePharmacoepidemiology and Drug Safety, 2008
- Self-Reported Practices and Attitudes of US Oncologists Regarding Off-Protocol TherapyJournal of Clinical Oncology, 2008
- Drug use in children: cohort study in three European countriesBMJ, 2008
- Off-label Drug Use in Hospitalized ChildrenArchives of Pediatrics & Adolescent Medicine, 2007
- Drug related problems and off-label drug treatment in children as seen at a drug information centreEuropean Journal of Pediatrics, 2006
- Off-label Prescribing Among Office-Based PhysiciansArchives of internal medicine (1960), 2006
- Adverse Drug Event Surveillance and Drug Withdrawals in the United States, 1969-2002Archives of internal medicine (1960), 2005